Latest Gefitinib Stories

NT-113 is an Irreversible, Selective Pan-ErbB Tyrosine Kinase Inhibitor with Significant Capacity to Cross Blood Brain Barrier MENLO PARK, Calif., April 8, 2013 /PRNewswire/ -- Preclinical data showing high potency, excellent pharmacokinetics and single-agent anti-cancer activity of NT-113, a novel irreversible Pan-ErbB Tyrosine Kinase Inhibitor under development by NewGen Therapeutics, was presented in a poster session today at the American Association of Cancer Research Meeting in...

A review in the December issue of the journal Archives of Pathology & Laboratory Medicine by Paul Bunn Jr, MD, University of Colorado Cancer Center investigator and past president of ASCO, IASLC and AACI describes the current state of lung cancer care. “We’re in a new paradigm in which we realize this top cause of cancer deaths is actually a number of related diseases, each potentially with its own cause and cure,” Bunn says. The review describes the shift from blanketing lung...

Phase III data reported at ESMO 2012 New trial data showing improvements in the treatment of esophageal and gastrointestinal cancers were released today at the ESMO 2012 Congress of the European Society for Medical Oncology in Vienna. Phase III, randomized, double-blind, placebo-controlled trial of gefitinib versus placebo in esophageal cancer progressing after chemotherapy The first phase III trial to address the need for second-line treatments in esophageal cancer shows that...

RIDGEFIELD, Conn., Sept. 20, 2012 /PRNewswire/ -- Boehringer Ingelheim today announced that data from 13 abstracts assessing the efficacy and safety of two of its investigational oncology compounds - afatinib and nintedanib - were selected for presentation at the ESMO 2012 Congress (European Society for Medical Oncology) in Vienna, Austria, September 28 - October 2, 2012. These data represent Boehringer Ingelheim's commitment to further develop its oncology pipeline with the...

SAN DIEGO, Aug 29, 2012 /PRNewswire/ -- Proacta Incorporated announced today that the US Food and Drug Administration has allowed its Investigational New Drug (IND) Application for PR610, a hypoxia-activated, irreversible multi-kinase inhibitor (MKI) for the treatment of cancer. The IND allowance permits Proacta to initiate human clinical trials of this novel, first in class treatment. Initially, development will focus on patients with non-small cell lung cancer who have developed...

BOULDER, Colo., Aug. 23, 2012 /PRNewswire/ -- Biodesix today announced that VeriStrat results from two phase II advanced lung cancer trials will be presented at the upcoming 2012 Chicago Multidisciplinary Symposium in Thoracic Oncology. The first study will be presented by Karen Reckamp, MD (City of Hope Comprehensive Cancer Center) and reports on the analysis of pre-treatment serum samples from a Phase II study evaluating erlotinib or erlotinib plus high-dose celecoxib in advanced...

(Ivanhoe Newswire) --Almost twelve million -- that’s how many cancer patients are living in the U.S. But what happens when the patients are no longer responsive to the drugs created to treat them? It’s a problem researchers at Case Western Reserve University are working to better understand. Researchers say overactive epidermal growth factor receptor (EGFR) signaling has been linked to the development of cancer. They found many patients have developed resistance to the drug therapies...

RIDGEFIELD, Conn., June 4, 2012 /PRNewswire/ -- Boehringer Ingelheim Pharmaceuticals, Inc. today announced that the company's pivotal Phase III clinical trial, LUX-Lung 3, investigating afatinib as a first-line treatment in patients with stage IIIb or IV non-small cell lung cancer (NSCLC) harboring an epidermal growth factor receptor (EGFR) mutation, met its primary endpoint of progression-free survival (PFS). The study evaluated 345 patients with NSCLC across a variety of...

XALKORI NOW AVAILABLE IN CANADA KIRKLAND, QC, May 30, 2012 /CNW/ - Pfizer Canada is pleased to announce that XALKORI(®) (crizotinib) is now available in Canada. Recently approved with conditions by Health Canada, XALKORI is an oral monotherapy for patients with anaplastic lymphoma kinase (ALK)-positive advanced or metastatic non-small cell lung cancer (NSCLC).(1) XALKORI is Pfizer Canada's first example of personalized medicine for people with ALK-positive non-small cell lung...

Xalkori Now Available in Canada KIRKLAND, QC, May 30, 2012 /CNW/ - Pfizer Canada is pleased to announce that XALKORI(®) (crizotinib) is now available in Canada. Recently approved with conditions by Health Canada, XALKORI is an oral monotherapy for patients with anaplastic lymphoma kinase (ALK)-positive advanced or metastatic non-small cell lung cancer (NSCLC).(1) XALKORI is Pfizer Canada's first example of personalized medicine for people with ALK-positive non-small cell lung...